Form 4: Ionis Pharmaceuticals Executive Acquires Stock Options
SEC Form 4
Eugene Schneider, EVP, Chf Clinical Develop Ofcr of Ionis Pharmaceuticals, reports the acquisition of stock options.
Summary
- Eugene Schneider, EVP, Chf Clinical Develop Ofcr of Ionis Pharmaceuticals, filed a Form 4 on January 3, 2025.
- The report details the acquisition of 22,000 non-qualified stock options with an exercise price of $34.69 on January 2, 2025.
- The options vest over a period of 4 years, starting with 25% vesting on January 2, 2026, and the remainder vesting in 36 equal monthly installments.
- Following the transaction, Schneider directly owns 22,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it is a standard reporting of stock option grants.
Positives
- The acquisition of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance.
Future Outlook
NA
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
- The grant incentivizes the executive to improve company performance, which could benefit all stakeholders.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of stock option grant and transaction. |
| 01/02/2026 | Date when 25% of the stock options vest. |
| 01/01/2035 | Expiration date of the stock options. |
| 01/03/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.